Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide in Non-Cirrhotic NASH with Fibrosis (Phase 2b/3)
CTR20222796Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of cotadutide in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by AstraZeneca. Started Oct 2022; status: terminated.
02
Drugs
cotadutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20222796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222796.